The Dermatology Digest

NOVEMBER 4, 2024

The EU Medical Device Regulation (MDR) certification gave its nod to four injectable hyaluronic acid (HA) gel fillers from Evolus under the brand name Estyme, The CE Mark certification, through the new MDR process, represents more stringent requirements, designed to ensure the safety, efficacy, and quality of medical devices sold in Europe.

Injections 68

Injections Medical Portfolios Branding 68

The Dermatology Digest

DECEMBER 18, 2024

Food and Drug Administration (FDA) has approved STEQEYMA (ustekinumab-stba), a biosimilar to STELARA (ustekinumab), for subcutaneous injection or intravenous infusion in adult and pediatric patients with plaque psoriasis and psoriatic arthritis, as well as adult patients with Crohn’s disease and ulcerative colitis. immunology market.”

Portfolios 69

Portfolios Injections Office Safety 69

The Dermatology Digest

MARCH 5, 2024

Food and Drug Administration has approved JUVÉDERM VOLUMA XC for injection in the temple region to improve moderate to severe temple hollowing in adults age 21 and older. The Allergan Medical Institute (AMI) team can train aesthetic providers on safe and effective treatments using the Allergan Aesthetics portfolio to address 90% of the face.

Portfolios 74

Portfolios Injections Training Facials 74

AAAMS

APRIL 18, 2024

Introduction to Injectable Training Courses Injectable training courses are your fastest ticket from being a beginner to a pro in the cosmetic industry. The journey starts with understanding what injectables are – substances like Botox and fillers that enhance facial features and diminish and promote a youthful appearance.

Injections 40

Injections Training Legal Safety 40

The Dermatology Digest

SEPTEMBER 9, 2024

It incorporates Polyglutamic Acid (PGA), a peptide known for its hydrating properties The non-injectable Elastiderm Advanced Filler Concentrate is formulated with Acetyl Hexapeptide-1, to smooth wrinkles and add volume.

Portfolios 36

Portfolios Dermatology Injections Marketing 36

The Dermatology Digest

MARCH 5, 2024

The Phase 1 trial is a first-in-human, randomized, double-blind, placebo-controlled study designed to evaluate the safety and PK of APG777 in healthy volunteers. The study enrolled 40 healthy adult participants into three single-ascending dose (SAD) and two multiple-ascending dose (MAD) cohorts.

Injections 36

Injections Safety Sustainability Clinic 36

The Dermatology Digest

JULY 1, 2024

Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for PYZCHIVA (ustekinumab-ttwe) subcutaneous injection and intravenous infusion as a biosimilar to Stelara (ustekinumab). Samsung Bioepis has seven biosimilars approved in the US and four commercially available as of June 2024.

Portfolios 74

Portfolios Safety Clinic Injections 74